Pfizer’s updated COVID shot effective against ‘Eris’ variant in mice study

Pfizer's vaccine against coronavirus disease (COVID-19) is authorized in Georgia for ages over 12 years. This supply pictured is at Dekalb Pediatric Center in Decatur

A supply of Pfizer’s vaccine against coronavirus disease (COVID-19) is seen at Dekalb Pediatric Center, after it is authorized in Georgia for ages over 12 years, in Decatur, Georgia, U.S. May 11, 2021. REUTERS/Chris Aluka Berry/File photo Acquire Licensing Rights

Aug 17 (Reuters) – Pfizer Inc (PFE.N) said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the “Eris” subvariant in a study conducted on mice.

Pfizer, along with its German partner BioNTech SE (22UAy.DE), as well as other COVID-19 vaccine makers Moderna (MRNA.O) and Novavax (NVAX.O) have created versions of their shots, which are aimed at the XBB.1.5 subvariant.

EG.5, nicknamed by some as “Eris“, is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant.

EG.5 accounted for about more than 17% of COVID-19 cases in the United States, according to the latest government data.

In the United States, COVID-19 related hospitalizations are up more than 40% off of recent lows hit in June, but are still more than 90% below peak levels hit during the January 2022 Omicron outbreak.

EG.5 has also been detected in China, South Korea, Japan and Canada, among other countries.

The World Health Organization classified EG.5 as a “variant of interest”, indicating that it should be more closely watched than others because of mutations that might make it more contagious or severe.

Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar

Our Standards: The Thomson Reuters Trust Principles.

Acquire Licensing Rights, opens new tab

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to content